Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070546 · ClinicalTrials.gov registry record · Phase 3
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,124
- Enrollment target
NCT05070546 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 1,124 participants.
The verdict
NCT05070546, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,124 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.
Interventions
- OTHER Placebo
- BIOLOGICAL Ad26.RSV.preF-based Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,124 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2022-08-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070546
The ClinicalTrials.gov registry entry for NCT05070546 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05070546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05070546 about?
NCT05070546 is a clinical study titled "A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection". The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.
What is the current status of trial NCT05070546?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,124 participants. The study started on 2021-09-29. Estimated completion is 2022-08-12.
What interventions are being tested in trial NCT05070546?
The interventions under investigation include: Placebo (OTHER), Ad26.RSV.preF-based Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05070546?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.